Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2013

Recipharm, Synthonics Partner to Promote Drug Delivery Tech

  • Recipharm Pharmaceutical Development and Synthonics have entered a dual-promotion agreement through which the former firm’s customers will have full access to the latter company’s metal coordination chemistry, which has been shown to improve drug delivery and absorption. Financial terms of the agreement were not disclosed.

    In a statement, Recipharm general manager Maria Lundberg noted: “The application of Synthonics’ chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products.”

    Synthonics’ Ken Slepicka, CEO, added that his firm believes its chemistry will integrate well with Recipharm’s existing solutions.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »